Prithviraj Bose
@bose_prithviraj
Followers
1K
Following
6K
Media
32
Statuses
445
Professor, Leukemia at MD Anderson; Co-section Head, section of myeloproliferative neoplasms. Tweets reflect my own views; not necessarily my institution's.
Houston, TX
Joined November 2020
Was an honor to join this all-star lineup at the New England Hematologic Diseases Symposium yesterday! @Dr_AmerZeidan thanks so much for inviting me to this outstanding meeting!
1
2
18
Excited to share the results of the Global Phase III trial #SurpassET demonstrating superiority of ROPEG INFa2b for 2L for patients with essential thrombocythemia #ET @AtriumHealth @LevineCancer @wakeforestmed
https://t.co/GEwyYIZXzc
1
6
21
Check out our modified Delphi consensus effort to define disease progression and modification in PV https://t.co/f3lx3xdjJa
#MPNSM @bose_prithviraj @RaajitRampal #johnmascarenhas
link.springer.com
Annals of Hematology - Within 15 years of diagnosis, around 15% of polycythemia vera (PV) cases progress to post-PV myelofibrosis, and around 3% transform to acute myeloid leukemia within 10 years....
0
1
10
An honor and a pleasure to speak yesterday at the 87th annual meeting of the JSH in Kobe, followed by a stimulating discussion on mutational testing afterwards! Great to see Japanese colleagues building elegantly on the pioneering work from our group on the role of BM fibrocytes
0
1
21
Pleasure to speak today at Singapore General Hospital on their MPN day as part of their 40th anniversary celebrations alongside @jjkiladjian! Very much enjoyed the discussion afterwards, thanks for having us! #MPNSM
4
1
24
All 4 of the FDA-approved JAK inhibitors for myelofibrosis have unique toxicity profiles that all patients and physicians must be aware of, said Prithviraj Bose, MD. https://t.co/mJNfFZElWw
#myelofibrosis #SOHO2025 | @bose_prithviraj @MDAndersonNews
cancernetwork.com
All 4 FDA-approved JAK inhibitors for myelofibrosis have unique toxicity profiles that all patients and physicians should know, said Prithviraj Bose, MD.
1
1
6
Now that #SOHO25 is completed, tune in to a few #HealthcareUnfiltered EXPRESS quick episodes on emerging therapies and data in various heme cancers. This week, @bose_prithviraj of @MDAndersonNews joins me to share what to watch for in MPNs. Check it out coming later this week.
0
1
6
🚨We've just published a new podcast episode! This episode compiles some of our highlights from #iwMPN25, covering novel frontline approaches to #Myelofibrosis management, cardiovascular health in MPNs & the application of AI in the space. 🎧 Listen now 👉
0
3
8
What an honor for @MDAndersonNews to again be #1 in the nation in cancer care, according to @USNews. I am deeply appreciative of everyone in our MD Anderson community: each of you played a role in this extraordinary accomplishment as we work together to #EndCancer.
MD Anderson is proud to be named #1 in the nation for cancer care in @USNews’“Best Hospitals” ranking. Read more: https://t.co/6DKYn4XAp5
#BestHospitals #EndCancer
8
24
132
🙌 ICYMI: in this roundtable discussion, @bose_prithviraj, @n_gangat, @pankitvachhani, and @aMyeloidPersona explore patient-centered approaches within the current treatment paradigm for #myelofibrosis. ➡️ https://t.co/g14vtZZY3p
0
1
8
Wrapping up a tour of the Sintra Pena Palace on a hot day here in Lisbon! @AYACOUB7 @MKremyanskaya @bose_prithviraj #MPNSM #iwMDSMPN2025
4
1
27
Important practice relevant data on anemia supportive agents used in combination with rux in the large JUMP trial nicely presented by @pankitvachhani at #EHA25. And that’s not even considering luspatercept. #MPNSM
0
0
12
A very proud mentor moment of @KuykendallMd for amazing presentation at ASCO plenary session @MoffittNews
6
12
56
Happy to share our latest review on the latest JAKi (granted not so new any more) to be approved for MF! Great job Ruchi Desai and thanks @pankitvachhani for the creative title! #MPNSM
tandfonline.com
Momelotinib is a small molecule inhibitor of JAK1, JAK2, and ACVR1 that is approved by the FDA and EMA for adults patients with intermediate/high risk myelofibrosis (MF) and anemia. Inhibition of t...
1
4
23
In the next installment of the #myelofibrosis roundtable rom #HOPLive, the panel discusses patient-centered approaches in today’s treatment paradigm. @bose_prithviraj @n_gangat @pankitvachhani @aMyeloidPersona 📺 Watch now! https://t.co/SE2QKX03Fs
0
3
9
In the second #myelofibrosis roundtable segment from #HOPLive, @bose_prithviraj, @n_gangat, @pankitvachhani, and @aMyeloidPersona dive into the current treatment landscape and ongoing clinical research shaping the future of care. 📺 Watch now! https://t.co/gKVKrFtkKI
0
2
4
In this #HOPLive roundtable discussion, Drs. @bose_prithviraj (@MDAndersonNews), @n_gangat (@MayoClinic), @pankitvachhani (@ONealCancerUAB), and @aMyeloidPersona (@cityofhope) explore the latest advancements in the molecular biology of #myelofibrosis. ➡️ https://t.co/NAhgqoKupn
0
2
4